No preventive benefits found for widely used kidney cancer drugs

Two widely used targeted therapy drugs— approved by the FDA for use in metastatic kidney cancer —are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to new research results.



from Today's Healthcare News -- ScienceDaily http://ift.tt/1LzO6So